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Abstract 
 
Endometrial cancer, the most common gynecologic malignancy, is a hormonally-regulated 
disease. Response to progestin therapy positively correlates with hormone receptor expression, in 
particular progesterone receptor (PR). However, many advanced tumors lose PR expression. We 
recently reported that the efficacy of progestin therapy can be significantly enhanced by 
combining progestin with epigenetic modulators, which we term “molecularly enhanced 
progestin therapy.” What remained unclear was the mechanism of action and if estrogen receptor 
α (ERα), the principle inducer of PR, is necessary to restore functional expression of PR via 
molecularly enhanced progestin therapy. Therefore, we modeled advanced endometrial tumors 
that have lost both ERα and PR expression by generating ERα-null endometrial cancer cell lines. 
CRISPR-Cas9 technology was used to delete ERα at the genomic level. Our data demonstrate 
that treatment with a histone deacetylase inhibitor (HDACi) was sufficient to restore functional 
PR expression, even in cells devoid of ERα. Our studies also revealed that HDACi treatment 
results in marked downregulation of the oncogene Myc. We established that PR is a negative 
transcriptional regulator of Myc in endometrial cancer in the presence or absence of ERα, which 
is in contrast to studies in breast cancer cells. First, estrogen stimulation augmented PR 
expression and decreased Myc in endometrial cancer cell lines. Second, progesterone increased 
PR activity yet blunted Myc mRNA and protein expression. Finally, overexpression of PR by 
adenoviral transduction in ERα-null endometrial cancer cells significantly decreased expression 
of Myc and Myc-regulated genes. Analysis of the Cancer Genome Atlas (TCGA) database of 
endometrial tumors identified an inverse correlation between PR and Myc mRNA levels, with a 
corresponding inverse correlation between PR and Myc downstream transcriptional targets 
SRD5A1, CDK2 and CCNB1. Together, these data reveal a previously unanticipated inverse 
relationship between the tumor suppressor PR and the oncogene Myc in endometrial cancer 
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Introduction 
 
Uterine endometrial cancer is the most common gynecology malignancy. Over 52,000 cases are 
diagnosed each year, and American women have a lifetime risk of 1:11 [1]. The uterine endometrium is 
exquisitely sensitive to steroid hormones. Estrogen acting through the estrogen receptor (ER: ERα and 
ERβ), drives proliferation, while progesterone acts through the progesterone receptor (PR: PRA and 
PRB) to counteract these effects by inducing differentiation, promoting apoptosis, and inhibiting 
invasion [2]. Based on the role of progesterone as a tumor suppressor in the endometrium, progestin-
based hormonal therapy has been used to treat endometrial hyperplasia and endometrial cancer for 
more than 60 years [3]. However, hormonal therapy has typically been successful only in tumors where 
hormone receptors are expressed. Our group and other groups have reported that the expression of PR 
positively correlates with a favorable prognosis and response to progestin treatment [3,4], whereas loss 
of PR expression underlies treatment failure. This limits the impact of hormonal therapy in advanced 
disease where receptors are lost. 
In our recently published study, we provide compelling evidence that it is possible to convert a PR-
negative cancer into a PR-positive cancer using epigenetic modulators [5]. This approach enhances 
sensitivity to progestin therapy in tumors with low levels of PR and induces progestin sensitivity in 
tumors that were never responsive. We propose that the efficacy of progestin therapy can be 
significantly enhanced by combining it with epigenetic modulators, which we term “molecularly 
enhanced progestin therapy.” 
To investigate if this molecularly enhanced progestin therapy can be applied to advanced endometrial 
cancer patients with ERα and PR negative tumors; we generated ERα null endometrial cancer cell lines 
by applying novel CRISPR-Cas9 technology to delete ERα at the genomic level (ESR1). Our data 
demonstrate that treatment with an HDACi is sufficient to 
restore functional PR expression, even in cells devoid of ERα. 
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Our studies also revealed a previously unanticipated inverse correlation between PR and the oncogene 
Myc in endometrial cancer, suggesting that HDACi treatment provides an additional advantage of Myc 
downregulation. We report an in-depth analysis of this correlation and hypothesize that loss of myc 
underlies the differentiating effects of progestin therapy. 
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Materials and Methods 
 
Antibodies and Reagents 
 
Estradiol (#E2257) and progesterone (#P6149) were obtained from Sigma Aldrich and resuspended in 
ethanol. Panobinostat (LBH589) was purchased from Selleck Chemicals and resuspended in DMSO. 
Antibodies against PRA/B (#3153), PRB (#3157), FOXO1 (#2880) and Myc (#13987) were from Cell 
Signaling. HSP90 antibody (ADI-SPA-835) was from Enzo. ERα antibody (sc-8002) was from Santa 
Cruz. β-actin antibody (#A1978) was obtained from Sigma Aldrich. 
 
Cell Lines and Cell Culture 
 
ECC-1 endometrial cancer cells were purchased from ATCC and grown according to the recommended 
guidelines. Ishikawa H endometrial cancer cells [6] (gift from Dr. Erlio Gurpide, New York University) 
were grown in DMEM media supplemented with 10% fetal bovine serum (regular FBS, r-FBS) or 
charcoal-stripped FBS (cs-FBS, life technologies, #12676–011) and penicillin-streptomycin (Gibco). 
Before addition of progesterone (P4) to cells, cell growth media with 10% FBS was replaced with 
growth media containing 5% charcoal-stripped serum to remove steroids from FBS. 
 
Generation of ERα Knockout Cells 
 
Genomic deletions of ERα (ESR1) were created in ECC1 cells using three pairs of chimeric single 
guide RNAs (sgRNAs) as previously described [7]. Briefly, sgRNA oligos were synthesized and cloned 
into the lentiCRISPR transfer plasmid for virus production. Viral vectors were produced in HEK293T 
cells, followed by infection of ECC1 cells as described [7]. ECC1-ESR1 CRISPR knockout (KO) cells 
were selected with 2 μg/ml puromycin after 48 hours of transduction. ECC1-ESR1 CRISPR KO cells 
were grown at low density for 2 weeks 
to select clones. ERα expression was determined by Western blotting to identify clones with no 
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or low ERα protein expression. ECC1-ESR1 CRISPR KO clones were maintained in media 
supplemented with 5 μg/ml puromycin. 
 
Adenoviral Expression of PR 
 
ECC1-ESR1 CRISPR KO clone 1–12 and 2–12 was infected with adenoviral vectors encoding PRA, 
PRB, or PRA/B or an empty vector control (Adcontrol) using a multiplicity of infection (MOI) of 10 
viral particles per cell as previously described [8]. An MOI of 10 viral particles per cell was employed 
to obtain PR expression levels roughly equivalent to the late proliferative phase of the menstrual cycle. 
 
Real-Time PCR 
 
Total RNA was extracted from cultured cells using the miRvana miRNA Isolation kit (Ambion, Life 
Technologies). RNA yield and purity was assessed using a NanoDrop Model 1000 
spectrophotometer (Thermo Scientific). Total RNA (500 ng) was oligo-dT reverse transcribed with 
SuperScript III (Invitrogen, Life Technologies). Real-time PCR was performed in triplicate on an 
Applied Biosystems Model 7900 Genetic Analyzer under standard conditions. Results were 
quantitated using the comparative cycle threshold (ΔΔCt) method [9]. Data were normalized to 18S 
rRNA. 
 
Western Blotting 
 
Following treatment, cells were solubilized in cold NP-40 cell lysis buffer (150 mM NaCl, 50 mM 
Tris/HCl, pH 7.4, 1% NP-40 with a protease and phosphatase inhibitor cocktail from Pierce) and then 
sonicated to release nuclear proteins. Lysates were analyzed by Western blotting with specific primary 
and HRP-conjugated secondary antibodies. For detection of PR protein, a combination of the PRA/B 
and PRB antibodies at a 1:1000 dilution each was used. 
9  
TCGA Data Analysis 
 
Patient information was downloaded from The Cancer Genome Atlas Data Portal (https://tcga- 
data.nci.nih.gov/tcga/) maintained by National Cancer Institute and National Human Genome Research 
Institute. Gene expression was assayed based on RNASeq conducted on the Illumina platform and was 
downloaded from NCI’s Cancer Genomics Hub (https://cghub.ucsc.edu/). 
The calculated expression was for all reads aligning to a particular gene per sample. There were a total 
of 379 endometrial cancer patients eligible for gene expression analysis. Patients were divided into 
four groups: endometrioid endometrial carcinoma grade 1, grade 2, grade 3 and serous grade 3 which 
includes cases designated as high grade and mixed histology type. 
 
Statistical Analysis 
 
Student’s t-test was used for comparisons of two groups. For TCGA data analysis, statistical analysis 
and data plotting were conducted with R Studio, and correlation analysis was performed with Spearman 
method. Statistical significance was concluded with p value < 0.05. 
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Results 
 
Modeling Loss of ERα in Endometrial Cancer Cells 
 
To mimic more advanced endometrial cancer which is associated with loss of ERα and PR, we applied 
CRISPR-Cas9 technology to delete ERα at the genomic level (ESR1) in the ERα- and PR-positive 
ECC1 endometrial cancer cells using three different sgRNA sequences [7]. These cells are denoted as 
ECC1-ESR1 CRISPR knockout (KO) cells. We next selected individual clones from cells transfected 
with each of the three sgRNAs. We confirmed that the majority of clones had complete deletion of ERα 
at the protein level, though clone 3–5 had a low level of residual ERα as compared to parental ECC1 
cells (Fig 1). Consistent with ERα as the principle inducer of PR expression, loss of ERα resulted in loss 
of PR as well as a reduction in the PR target gene FOXO1 (Fig 1). 
Fig 1. HDAC inhibitor (panobinostat, 
LBH589) upregulates PR expression and 
downregulates Myc in ERα knockout 
endometrial cancer cells lines. 
Using CRISPR-Cas9 technology, ERα was 
silenced at the genomic level in ECC1 cells. 
Ishikawa, parental ECC1 cells and individual 
ESR1 KO ECC1 clones were treated with 20 
nM LBH589 for 24 hr. Expression of ERα, PR, 
FOXO1, and Myc were evaluated by Western 
blotting. β-actin serves as a loading control. 
 
 
 
 
HDAC Inhibitor Restores PR Expression in ECC1-ESR1 CRISPR KO Endometrial Cancer Cells 
Lines 
We next asked if ERα expression is required for HDACi-mediated induction of PR, which we 
previously reported as a mechanism to restore sensitivity to progestin-based therapy [5,10]. In all 
ECC1-ESR1 CRISPR KO clones, treatment with the pan-HDAC inhibitor LBH589 (panobinostat, 
Novartis) substantially increased PR protein expression and activity as 
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determined by expression of the PR target gene, FOXO1 (Fig 1). Note that cells were maintained in 
serum that contains progesterone. As a control, we also examined PR levels in parental ECC1 cells and 
Ishikawa cells, which have modest baseline PR expression. Consistent with our previous studies [5,10], 
LBH589 promoted robust PR expression in these cell lines. 
Taken with our previously published data that the combination of LBH589 and progesterone decreases 
colony formation by parental Ishikawa cells [5], these data suggest that, even in patients with loss of 
both ERα and PR, it may be possible to achieve sensitivity to progestin therapy with an epigenetic 
modulator. 
 
HDAC Inhibitor Represses Oncogene Myc Expression in Endometrial Cancer Cells 
 
As a control, we also assessed expression of the oncogene Myc based on several reports that ERα and 
PR promote transcription of Myc in breast cancer [11–13]. Unexpectedly, expression of Myc was 
unchanged in untreated ECC1-ESR1 CRISPR KO cells despite loss of ERα and PR expression. 
However, HDACi treatment, in addition to inducing PR as described above, completely repressed Myc 
protein expression. We also observed a decrease in Myc and an upregulation of PR in the parental 
ECC1 cells as well as another endometrial cancer cell line, Ishikawa, following treatment with 
LBH589. These data identify an inverse relationship between Myc and PR in endometrial cancer cells. 
We also utilized higher concentrations of LBH589 to determine if Myc levels could be further 
suppressed. In both parental and ECC1-ESR1 CRISPR KO endometrial cancer cells, PR levels were 
progressively elevated in response to increasing concentrations of LBH589, with a corresponding dose-
dependent decrease in Myc expression (Fig 2). These findings confirm our observation of the inverse 
correlation between PR and Myc expression in Fig 1 and suggest that higher concentrations of LBH589 
may be required to restore PR levels in tumors with long-term loss of hormone receptor expression. 
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Fig 2. Higher concentrations of 
HDACi LBH589 further increase 
PR and decrease Myc expression in 
endometrial cancer cells. 
Cells were treated with indicated 
concentrations of LBH589 for 24 hr 
and protein expression analyzed by 
Western blotting. β-actin serves as a 
loading control. 
 
 
Estrogen Stimulation Increases PR and Decreases Myc Expression in Endometrial Cancer Cell 
Lines 
The inverse correlation between PR and Myc expression in Figs 1 and 2 challenges the well- 
accepted paradigm in breast cancer that PR promotes Myc expression [12,14]. We first confirmed 
that estrogen stimulation of MCF7 cells, which contain endogenous ERα and PR, results in robust 
expression of PR and Myc, with anticipated ligand-mediated ERα downregulation (S1 Fig). Addition 
of progesterone further increased Myc levels, in line with previous studies [12,14]. By contrast, 
estrogen stimulation of endometrial cancer cells with endogenous ERα expression induced PR 
expression, with a concomitant decrease (Ishikawa cells) or no further increase (ECC1 cells) in Myc 
protein levels (Fig 3). 
 
Fig 3. Activation of ERα with estrogen 
simultaneously increases PR expression and 
decreases Myc expression in endometrial 
cancer cells. 
Ishikawa and ECC1 cells were treated with 10 
nM estradiol (E2) for indicated times. PR, Myc 
and ERα protein expression was measured by 
Western blotting. Hsp90 serves as loading 
control. 
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PR Negatively Regulates Myc Expression and Activity in Endometrial Cancer Cell To 
investigate if PR mediates Myc downregulation in endometrial cancer cells, we treated Ishikawa 
cells, which have low baseline ERα and PR levels (Fig 3), with LBH589 in the 
absence or presence of progesterone for 0–72 hrs. Experiments were performed in charcoal- stripped 
serum to remove hormones. Treatment with progesterone produced a time-dependent decrease in Myc 
protein levels, and the addition of HDACi accentuated this effect (Fig 4A). We also assessed Myc 
transcriptional activity by examining mRNA levels of Myc target genes. Consistent with Western blot 
data, mRNA levels of Myc were decreased by more than 90% following treatment with LBH589, and 
addition of progesterone resulted in a further decrease (Fig 4B). The Myc target genes CDK4, CAD, 
SRD5A1 and HES1 were repressed in response to LBH589+progesterone (Fig 4B). 
 
Fig 4. The combination of HDACi and 
progesterone negatively regulates Myc 
expression and activity in endometrial 
cancer cells 
(A) Ishikawa cells were treated with 20 
nM LBH589, 100 nM progesterone (P4) 
or the combination for the indicated times. 
PR and Myc protein expression was 
measured by Western blotting. β-actin 
serves as a loading control. (B) Expression 
of Myc and its downstream genes (CDK4, 
CAD, SRD5A1 and HES1) were analyzed 
by qRT-PCR in Ishikawa cells were 
treated with 20 nM LBH589 -/+100 nM 
P4 for 4 or 24 hrs. Data were normalized 
to 18S and calculated as the fold change 
relative to control. * p < 0.05 vs. control. 
 
To investigate if PR mediates Myc downregulation in ERα-null endometrial cancer cells, 
molecularly enhanced progestin therapy was applied in ECC1-ESR1 CRISPR KO cells. 
Consistent with Fig 4, similar results were obtained in ERα-null cancer cells (Fig 5). 
Specifically, treatment with LBH589 increased expression of PR and decreased expression of Myc and 
its downstream transcriptional targets, CDK4 and CAD. This effect was amplified by 
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addition of progesterone (Fig 5A). This loss of Myc expression was confirmed at the protein level 
(Fig 5B). 
 
Fig 5. Downregulation of Myc and 
downstream target genes in response to 
HDACi alone and in combination with 
progesterone. 
 
(A) ECC1-ESR1 CRISPR KO clone 1–12 was 
treated with 100 nM P4 for 16 hr, 20 nM 
LBH589 for 24 hr, or the combination, 
followed by analysis of PR, Myc, and PR target 
genes by qRT-PCR. Data were normalized to 
18S and calculated as the fold change relative 
to control. Results are representative of 3 
independent experiments; * p < 0.05 vs. 
DMSO; # p < 0.05 vs. LBH589. (B) ECC1- 
ESR1 CRISPR KO clones were treated as in 
(A), followed by analysis of PR and Myc 
protein levels by Western blotting. β-actin 
serves as a loading control. 
 
 
 
 
 
 
To provide further evidence for the link between PR and Myc downregulation, we overexpressed PRA 
and PRB in ECC1-ESR1 CRISPR KO clone 1–12. We first confirmed that exogenous expression of 
PRA or PRB by adenoviral transduction leads to robust overexpression of PR and also induction of PR 
downstream gene AREG (Fig 6). 
Overexpression of PR resulted in Myc downregulation, and addition of progesterone further 
decreased mRNA levels of Myc and the Myc target gene, HES1 (Fig 6). These data support our 
hypothesis that PR negatively regulates Myc expression in endometrial cancer. 
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Fig 6. Overexpression of PR decreases Myc expression and activity 
ECC1-ESR1 CRISPR KO clone 1–12 was transduced with control adenovirus (Adcontrol) or 
adenovirus containing PRA, PRB, or PRA+PRB for 24 hr, followed by 100 nM P4 for an 
additional 24 hr. mRNA levels were quantified by qRT-PCR, normalized to 18S, and data 
expressed as fold change relative to Adcontrol in the absence of P4. Results are representative 
of 3 independent experiments; * p < 0.05 vs. Adcontrol; # p < 0.05 vs.–P4 in the same group. 
 
 
 
Inverse Correlation between PR and Myc in Endometrial Patient Tumors 
 
To investigate if there is an inverse correlation between PR and Myc expression in endometrial cancer 
patient samples, we analyzed RNA-Seq data from 379 endometrial tumors in the TCGA dataset. We 
observed a progressive decrease in PGR and ESR1 mRNA expression from endometrioid endometrial 
cancers to more aggressive serous tumors as defined by grade level (Fig 7A). On the contrary, Myc 
mRNA expression was increased significantly in high grade tumors relative to lower grades. The 
Spearman correlation method confirmed that the correlations of PGR with Myc and ESR1 with Myc are 
significant (Fig 7B and 7C). 
16  
Fig 7.  Inverse correlation 
of Myc with ESR1 and 
PGR in endometrial cancer 
TCGA data. 
 
(A) Boxplot of mRNA 
expression of PGR (left 
panel), ESR1 (middle panel) 
and Myc (right panel) was 
analyzed according to 
endometrial cancer grade in 
379 endometrial cancer 
patient tumors from TCGA 
database. Patients were 
divided into four groups: 
endometrioid type I grade 1 
(G1, n = 86), grade 2 (G2, n 
= 103), grade 3 (G3, n = 123) 
and serous type II grade 3 
(G3, n = 67). (B) Pairwise 
correlation analysis of PGR, 
ESR1 and Myc mRNA levels 
using Spearman method. The correlation coefficients and p values are shown. (C) Scatterplot to 
show the negative correlation in expression of two genes. Patients were plotted on the x-axis in 
order of increasing expression of a specific gene. Two regression lines were produced by 
simple linear regression analysis based on the expression of respective genes. Left: Expression 
of Myc (red) against PGR (black); right: expression of Myc (red) against ESR1 (black). 
 
 
To further validate the inverse correlation between PR and Myc in patient samples, we examined how 
PR correlated with Myc downstream genes SRD5A1, CCNB1 and CDK2. The Spearman correlation 
method demonstrated a strong negative correlation of PGR with SRD5A1, CCNB1 and CDK2 
expression (Fig 8). 
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Fig 8.  Inverse correlation of PR with Myc target genes in endometrial cancer TCGA data. 
(A) Pairwise correlation analysis of PGR and Myc downstream genes, SRD5A1, CCNB1 and CDK2 
using Spearman method. The correlation coefficients and p values are shown. (B-D) Scatterplots to 
show the positive or negative correlation of expression of two genes as in Fig 6C. (B) Expression of 
SRD5A1 (red) against PGR (black); (C) expression of CCNB1 (red) against PGR (black); and (D) 
expression of CDK2 (red) against PGR (black). 
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Discussion 
 
Endometrial cancer is a hormone regulated cancer wherein estrogen drives growth and progesterone 
suppresses proliferation and leads to differentiation. Response to progestin-based therapy positively 
correlates with hormone receptor expression, in particular progesterone receptor (PR), yet many 
advanced tumors are devoid of PR expression as well as ERα, the primary transcriptional inducer of PR. 
We recently found that PR expression can be restored by HDACi. Herein we extend these findings by 
reporting that PR expression can be restored in endometrial cancer cells, even those without ERα. These 
data are critical because they suggest that, even in patients with loss of both ERα and PR, it may be 
possible to restore sensitivity to progestin through combination treatment with an epigenetic modulator. 
Surprisingly, we also found that the oncogene Myc, which is known to be induced by ERα and PR in 
breast cancer cells, was markedly repressed by HDACi treatment, including in cells that lack ERα. 
Moreover, exogenous expression of PR by adenovirus promoted Myc downregulation, providing 
further evidence that PR negatively regulates Myc expression. Consistent with the observations in 
cancer cells, we found that PR and Myc are inversely correlated in endometrial tumors in TCGA 
dataset. We hypothesize that loss of Myc underlies the differentiating effects of progestin therapy in 
endometrial cancer. 
Myc is a well-characterized oncogene that plays a major role in the pathogenesis of many cancers 
[15,16]. Like other cancer types, Myc is highly expressed in endometrial tumors [17]. Studies in 
transgenic mouse models reveal that Myc inactivation results in rapid tumor regression and is 
frequently associated with hallmarks of cellular differentiation and apoptosis [18,19]. Despite clear 
evidence for the highly oncogenic role of Myc in many tumor types, including endometrial cancer, a 
specific small molecule inhibitor of Myc has remained elusive [20]. Current drug development 
strategies include targeting pathways upstream or downstream 
of Myc, such as the bromodomain and extra-terminal motif (BET) inhibitor. Indeed, inhibition 
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of BET in multiple myeloma results in remarkable downregulation of Myc expression and associated 
cell death [16]. Herein we identify another potential mechanism to blunt the oncogenic effects of Myc: 
PR-mediated suppression of Myc transcription. Therefore, molecularly enhanced progestin therapy not 
only enhances sensitivity to progestin by restoring functional PR expression [5,10], but also provides 
an additional advantage of downregulating Myc. 
Others have shown that Myc expression is regulated through epigenetic mechanisms. For example, 
HDACi-mediated repression of Myc expression has also been reported in head and neck squamous cell 
carcinoma cell lines [21]. The potential mechanism is up-regulation of MXI1 and SSB2, which inhibit 
the transcriptional activity of Myc [21]. However, our data suggest that the mechanism of Myc 
repression is through PR. First, treatment with progesterone in combination with HDACi produced a 
further decrease in Myc as compared to HDACi alone. Second, overexpression of PRA/B by 
adenovirus in ECC1-ESR1 CRISPR KO cells substantially decreased Myc expression in the absence of 
an HDACi, indicative of a PR- mediated effect rather than a general epigenetic effect. 
Several reports in breast cancer demonstrate that ERα and PR promote transcription of Myc through 
binding the estrogen response element (ERE) and progesterone response element (PRE) in the Myc 
promoter region [11,13,22,23]. The earliest report of a PRE in the Myc promoter region in T47D breast 
cancer cells was published in 1997 [14]. The observation that ERα and PR induce Myc expression is 
consistent with the phenomenon that progestins used in contraception drugs promote breast cancer 
growth in vitro and in vivo [24–26]. Here we report the converse effect in endometrial cancer, where 
expression of Myc inversely correlated with ERα and PR, both in endometrial cancer cell lines and in 
tumors from TCGA database. Control experiments in MCF7 breast cancer cells confirmed the positive 
correlation of Myc with ERα 
and PR in this cell type. Thus, the negative regulation of Myc by PR in endometrial cancer may 
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provide one explanation for the opposing effects of progesterone on proliferation in breast vs. 
endometrial cancer. 
In summary, we found that HDACi treatment of endometrial cancer cells provides the dual advantages 
of upregulating the tumor suppressor PR and downregulating the oncogene Myc. Unfortunately, single 
agent HDACi has limited clinical efficacy in solid tumors, and emerging studies are exploring the use 
of HDACi to “prime” tumors to other treatments [27, 28]. Based on our extensive studies of 
mechanisms of PR silencing in endometrial cancer, we suggest that HDACi can be used to prime 
endometrial tumors for responsiveness to progestin-based therapy, which we refer to as molecularly 
enhanced progestin therapy, via epigenetic modulation. Future studies are necessary to understand if 
combining an HDACi with progestin will restore PR, downregulate Myc, and lead to disease 
management. A first step may be to explore this combinatorial strategy in the neoadjuvant setting, 
which would provide the opportunity to examine PR and Myc levels in pre-treatment biopsies and in 
post-treatment surgical specimens obtained at the time of tumor cytoreduction. Another therapeutic 
opportunity is in the setting of advanced or recurrent endometrial cancer, where the majority of 
endometrial tumors have lost expression of PR. By integrating the epigenetic therapies into hormonal 
regimens, it may be possible to improve outcomes for endometrial cancer, a disease that is on the rise. 
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